Our subgroup analysis found an interesting result that in AD patients with only mild cognitive impairment, BACE1 inhibitors were associated with an exacerbation of cognitive decline in even more secondary efficacy outcomes and safety concerns remain. This evidence concerns the gene BACE1 and Alzheimer disease.